ANP32D

Across TCGA pan-cancer cohorts, ANP32D Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANP32D data layer compared with 18 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ANP32D Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANP32D expression acts as an unfavorable survival marker.

BLCA, LUAD, and COAD are the cancer types where ANP32D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
LUAD	OS	Median	All	0.338	0.834	.004	12	view →
COAD	DFS	Median	All	0.140	0.781	<.001	9	view →
READ	OS	Median	III,IV	0.287	0.748	.001	6	view →
GBM	DFS	Median	All	0.066	0.242	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANP32D–BLCA (DFS)

Open the BLCA breakdown →